Peritoneal Mesothelioma
Lining of the abdomen (peritoneum) — Approximately 20% of all mesothelioma cases
Overview
Peritoneal mesothelioma develops in the peritoneum, the thin membrane lining the abdominal cavity. It is the second most common form of mesothelioma and is linked to asbestos exposure, either through ingesting asbestos fibers or through fibers that migrate from the lungs to the abdomen.
The peritoneum is a serous membrane that lines the abdominal cavity and covers most abdominal organs. Asbestos fibers can reach the peritoneum through several pathways: direct ingestion of fibers, migration from the lungs through the lymphatic system, or translocation through the diaphragm. Once embedded in the peritoneal tissue, the fibers cause chronic inflammation and eventually malignant transformation.
Peritoneal mesothelioma has seen some of the most promising treatment advances in recent years. The combination of cytoreductive surgery (which removes visible tumors and affected peritoneal surfaces) with HIPEC (which bathes the abdominal cavity in heated chemotherapy) has significantly improved survival rates. Specialized cancer centers with experience in this procedure have reported median survival times exceeding four years.
Symptoms
- • Abdominal pain and swelling
- • Ascites (fluid buildup in the abdomen)
- • Unexplained weight loss
- • Nausea and vomiting
- • Loss of appetite
- • Bowel obstruction or changes in bowel habits
- • Fatigue and weakness
- • Abdominal lumps or masses
Diagnosis
- • CT scan of the abdomen and pelvis
- • PET scan to identify cancer spread
- • Laparoscopy (camera-guided examination of the abdominal cavity)
- • Peritoneal biopsy — required for definitive diagnosis
- • Blood tests including CA-125 and SMRP markers
- • MRI for detailed imaging of abdominal structures
- • Paracentesis (fluid removal for analysis)
Prognosis
Peritoneal mesothelioma has shown improved outcomes with HIPEC treatment. Median survival is approximately 53 months with cytoreductive surgery and HIPEC, compared to about 12 months with chemotherapy alone. Some patients have achieved long-term survival of 7+ years with aggressive treatment. The epithelioid cell type responds best to treatment.
Treatment Options
- • Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) — the gold standard treatment
- • Debulking surgery to remove as much tumor as possible
- • Systemic chemotherapy with pemetrexed and cisplatin
- • Immunotherapy for unresectable disease
- • Intraperitoneal chemotherapy delivered directly into the abdominal cavity
- • Radiation therapy in selected cases
- • Clinical trials for novel treatments
- • Palliative care including paracentesis for fluid management
Legal Considerations
Peritoneal mesothelioma may result from swallowing asbestos fibers or from fibers that travel through the lymphatic system after inhalation. Cases may involve occupational exposure, environmental contamination, or secondary exposure through contaminated clothing. The connection to asbestos exposure is well-established in medical literature.
Average Settlement Range
$1 million – $2.5 million
Your Legal Rights with Peritoneal Mesothelioma
A peritoneal mesothelioma diagnosis establishes a strong basis for legal action against the companies responsible for your asbestos exposure. The medical literature clearly links this cancer to asbestos, and courts across the country have consistently awarded significant compensation to patients and their families.
You may be entitled to compensation through personal injury lawsuits, asbestos trust fund claims, and — if you are a veteran — VA disability benefits. These claims can be pursued simultaneously. Over 95% of mesothelioma cases settle before trial, with average settlements in the range of $1 million – $2.5 million.
Mesothelioma attorneys work on contingency, meaning you pay nothing unless they secure compensation for you. Do not delay — every state has a statute of limitations that sets a firm deadline for filing your claim.
Understanding Treatment for Peritoneal Mesothelioma
Treatment for peritoneal mesothelioma depends on the stage of the disease, the cell type identified in your biopsy, your overall health, and your treatment goals. Seeking a second opinion from a mesothelioma specialist at a major cancer center is strongly recommended, as these physicians have the most experience with this rare cancer and access to the latest treatment protocols and clinical trials.
A multimodal approach — combining two or more treatment types such as surgery, chemotherapy, radiation, or immunotherapy — generally produces the best outcomes. Your oncologist will develop an individualized treatment plan and can discuss the benefits and risks of each option. Palliative care to manage symptoms and improve quality of life is an important component of treatment at any stage.
Frequently Asked Questions: Peritoneal Mesothelioma
What is HIPEC treatment for peritoneal mesothelioma?+
HIPEC (Heated Intraperitoneal Chemotherapy) is delivered during surgery after cytoreductive surgery removes visible tumors from the abdominal cavity. Heated chemotherapy solution is circulated directly through the abdomen to kill remaining microscopic cancer cells. The combination of CRS and HIPEC is the gold standard for peritoneal mesothelioma, achieving median survival times exceeding 53 months — significantly better than systemic chemotherapy alone.
Does peritoneal mesothelioma have a better prognosis than pleural?+
Generally, yes. Peritoneal mesothelioma treated with cytoreductive surgery and HIPEC has shown median survival of approximately 53 months, compared to 12-21 months for pleural mesothelioma. Some peritoneal patients have survived 7 or more years with aggressive treatment. The improved prognosis is largely due to the effectiveness of the CRS/HIPEC approach. However, outcomes still depend on cell type, tumor burden, and overall health.